{
	"@context": {
		"rdf": "http://www.w3.org/1999/02/22-rdf-syntax-ns#",
		"dct": "http://purl.org/dc/terms/",
		"owl": "http://www.w3.org/2002/07/owl#",
		"xsd": "http://www.w3.org/2001/XMLSchema#",
		"rdfs": "http://www.w3.org/2000/01/rdf-schema#",
		"@vocab": "http://ld.nice.org.uk/ns/bnf#",
		"bnf": "http://ld.nice.org.uk/ns/bnf/",
		"nicebnf": "http://ld.nice.org.uk/ns/bnf#",
		"route": "http://ld.nice.org.uk/ns/bnf/Route#",
		"patientGroup": "http://ld.nice.org.uk/ns/bnf/PatientGroup#",
		"indication": "http://ld.nice.org.uk/ns/bnf/Indication#",
		"sideEffect": "http://ld.nice.org.uk/ns/bnf/SideEffect#",
		"classification": "http://ld.nice.org.uk/ns/bnf/Classification#",
		"isLinkedFrom": {
			"@container": "@set"
		},
		"hasInteraction": {
			"@container": "@set"
		},
		"hasMessage": {
			"@container": "@set"
		},
		"hasInteractionList": {
			"@container": "@set"
		},
		"isInteractionListOf": {
			"@container": "@set"
		}
	},
	"@graph": [
		{
			"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine",
			"@type": "InteractionList",
			"hasInteraction": [
				{
					"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962104",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962104_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eslicarbazepine\" outputclass=\"int-heading-drug\">Eslicarbazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"atorvastatin\" outputclass=\"int-drug\">atorvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eslicarbazepine   is predicted to   decrease   the exposure to   atorvastatin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "1",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Atorvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962105",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962105_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"carbamazepine\" outputclass=\"int-drug\">Carbamazepine</ph> <ph outputclass=\"int-magnitude\">slightly</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"eslicarbazepine\" outputclass=\"int-heading-drug\">eslicarbazepine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Carbamazepine   slightly   decreases   the exposure to   eslicarbazepine .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "2",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Carbamazepine</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962106",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962106_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"eslicarbazepine\" outputclass=\"int-heading-drug\">Eslicarbazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"combined hormonal contraceptives\" outputclass=\"int-drug\">combined hormonal contraceptives</ph>. <ph outputclass=\"int-action\">For FSRH guidance, see <xref format=\"dita\" href=\"treatment-summary/contraceptives-interactions.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP92512\">Contraceptives, interactions</xref></ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Eslicarbazepine   is predicted to   decrease   the efficacy of   combined hormonal contraceptives .  For FSRH guidance, see  Contraceptives, interactions .    \n\n"
						}
					],
					"hasOrder": "3",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Combined hormonal contraceptives</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962107",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962107_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"eslicarbazepine\" outputclass=\"int-heading-drug\">Eslicarbazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"cyproterone\" outputclass=\"int-drug\">cyproterone</ph> <ph outputclass=\"int-substanceQualifier\">with ethinylestradiol (co-cyprindiol)</ph>. <ph outputclass=\"int-action\">Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Eslicarbazepine   is predicted to   decrease   the efficacy of   cyproterone   with ethinylestradiol (co-cyprindiol) .  Manufacturer advises use alternative methods during treatment with, and for 28 days after, the enzyme inducing drug is stopped .    \n\n"
						}
					],
					"hasOrder": "4",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Cyproterone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962108",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962108_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"eslicarbazepine\" outputclass=\"int-heading-drug\">Eslicarbazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"desogestrel\" outputclass=\"int-drug\">desogestrel</ph>. <ph outputclass=\"int-action\">For FSRH guidance, see <xref format=\"dita\" href=\"treatment-summary/contraceptives-interactions.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP92512\">Contraceptives, interactions</xref></ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Eslicarbazepine   is predicted to   decrease   the efficacy of   desogestrel .  For FSRH guidance, see  Contraceptives, interactions .    \n\n"
						}
					],
					"hasOrder": "5",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Desogestrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962109",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962109_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"eslicarbazepine\" outputclass=\"int-heading-drug\">Eslicarbazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"erlotinib\" outputclass=\"int-drug\">erlotinib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Eslicarbazepine   is predicted to   decrease   the exposure to   erlotinib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "6",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Erlotinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962110",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962110_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eslicarbazepine\" outputclass=\"int-heading-drug\">Eslicarbazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"estradiol\" outputclass=\"int-drug\">estradiol</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eslicarbazepine   is predicted to   decrease   the efficacy of   estradiol .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "7",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Estradiol</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962111",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962111_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"eslicarbazepine\" outputclass=\"int-heading-drug\">Eslicarbazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"etonogestrel\" outputclass=\"int-drug\">etonogestrel</ph>. <ph outputclass=\"int-action\">For FSRH guidance, see <xref format=\"dita\" href=\"treatment-summary/contraceptives-interactions.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP92512\">Contraceptives, interactions</xref></ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Eslicarbazepine   is predicted to   decrease   the efficacy of   etonogestrel .  For FSRH guidance, see  Contraceptives, interactions .    \n\n"
						}
					],
					"hasOrder": "8",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Etonogestrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962112",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962112_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eslicarbazepine\" outputclass=\"int-heading-drug\">Eslicarbazepine</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"fosphenytoin\" outputclass=\"int-drug\">fosphenytoin</ph> and <ph otherprops=\"fosphenytoin\" outputclass=\"int-drug\">fosphenytoin</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"eslicarbazepine\" outputclass=\"int-heading-drug\">eslicarbazepine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eslicarbazepine   increases   the exposure to   fosphenytoin  and  fosphenytoin   decreases   the exposure to   eslicarbazepine .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "9",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Fosphenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962113",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962113_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eslicarbazepine\" outputclass=\"int-heading-drug\">Eslicarbazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"gefitinib\" outputclass=\"int-drug\">gefitinib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eslicarbazepine   is predicted to   decrease   the exposure to   gefitinib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "10",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Gefitinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962114",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962114_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"eslicarbazepine\" outputclass=\"int-heading-drug\">Eslicarbazepine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"glecaprevir\" outputclass=\"int-drug\">glecaprevir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Eslicarbazepine   potentially   decreases   the exposure to   glecaprevir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "11",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Glecaprevir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962115",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962115_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eslicarbazepine\" outputclass=\"int-heading-drug\">Eslicarbazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the effects of</ph> <ph otherprops=\"hormone replacement therapy\" outputclass=\"int-drug\">hormone replacement therapy</ph>. <ph outputclass=\"int-action\">Manufacturer advises caution</ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eslicarbazepine   is predicted to   decrease   the effects of   hormone replacement therapy .  Manufacturer advises caution .    \n\n"
						}
					],
					"hasOrder": "12",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Hormone replacement therapy</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962116",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962116_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eslicarbazepine\" outputclass=\"int-heading-drug\">Eslicarbazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"imatinib\" outputclass=\"int-drug\">imatinib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eslicarbazepine   is predicted to   decrease   the exposure to   imatinib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "13",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Imatinib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962117",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962117_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"eslicarbazepine\" outputclass=\"int-heading-drug\">Eslicarbazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"levonorgestrel\" outputclass=\"int-drug\">levonorgestrel</ph>. <ph outputclass=\"int-action\">For FSRH guidance, see <xref format=\"dita\" href=\"treatment-summary/contraceptives-interactions.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP92512\">Contraceptives, interactions</xref></ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Eslicarbazepine   is predicted to   decrease   the efficacy of   levonorgestrel .  For FSRH guidance, see  Contraceptives, interactions .    \n\n"
						}
					],
					"hasOrder": "14",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Levonorgestrel</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962118",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962118_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"eslicarbazepine\" outputclass=\"int-heading-drug\">Eslicarbazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"norethisterone\" outputclass=\"int-drug\">norethisterone</ph>. <ph outputclass=\"int-action\">For FSRH guidance, see <xref format=\"dita\" href=\"treatment-summary/contraceptives-interactions.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP92512\">Contraceptives, interactions</xref></ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Eslicarbazepine   is predicted to   decrease   the efficacy of   norethisterone .  For FSRH guidance, see  Contraceptives, interactions .    \n\n"
						}
					],
					"hasOrder": "15",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Norethisterone</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962119",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962119_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eslicarbazepine\" outputclass=\"int-heading-drug\">Eslicarbazepine</ph> <ph outputclass=\"int-effect\">increases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"phenytoin\" outputclass=\"int-drug\">phenytoin</ph> and <ph otherprops=\"phenytoin\" outputclass=\"int-drug\">phenytoin</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"eslicarbazepine\" outputclass=\"int-heading-drug\">eslicarbazepine</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eslicarbazepine   increases   the exposure to   phenytoin  and  phenytoin   decreases   the exposure to   eslicarbazepine .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "16",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Phenytoin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962120",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962120_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"eslicarbazepine\" outputclass=\"int-heading-drug\">Eslicarbazepine</ph> <ph outputclass=\"int-effectQualifier\">potentially</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"pibrentasvir\" outputclass=\"int-drug\">pibrentasvir</ph>. <ph outputclass=\"int-action\">Manufacturer advises avoid</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Eslicarbazepine   potentially   decreases   the exposure to   pibrentasvir .  Manufacturer advises avoid .    \n\n"
						}
					],
					"hasOrder": "17",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Pibrentasvir</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962121",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962121_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eslicarbazepine\" outputclass=\"int-heading-drug\">Eslicarbazepine</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"rosuvastatin\" outputclass=\"int-drug\">rosuvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eslicarbazepine   decreases   the exposure to   rosuvastatin .  Manufacturer advises monitor .    \n\n"
						}
					],
					"hasOrder": "18",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Rosuvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962122",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962122_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eslicarbazepine\" outputclass=\"int-heading-drug\">Eslicarbazepine</ph> <ph outputclass=\"int-magnitude\">moderately</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"simvastatin\" outputclass=\"int-drug\">simvastatin</ph>. <ph outputclass=\"int-action\">Manufacturer advises monitor and adjust dose</ph>.  </p>"
							},
							"hasEvidence": "Study",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eslicarbazepine   moderately   decreases   the exposure to   simvastatin .  Manufacturer advises monitor and adjust dose .    \n\n"
						}
					],
					"hasOrder": "19",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Simvastatin</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962123",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962123_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Moderate\" outputclass=\"int-message\">\n  <ph otherprops=\"eslicarbazepine\" outputclass=\"int-heading-drug\">Eslicarbazepine</ph> <ph outputclass=\"int-effectQualifier\">is predicted to</ph> <ph outputclass=\"int-effect\">decrease</ph> <ph outputclass=\"int-parameter\">the exposure to</ph> <ph otherprops=\"sorafenib\" outputclass=\"int-drug\">sorafenib</ph>. <ph outputclass=\"int-action\">Manufacturer makes no recommendation</ph>.  </p>"
							},
							"hasEvidence": "Theoretical",
							"hasImportance": "Moderate",
							"hasOrder": "1",
							"hasTextContent": "Eslicarbazepine   is predicted to   decrease   the exposure to   sorafenib .  Manufacturer makes no recommendation .    \n\n"
						}
					],
					"hasOrder": "20",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Sorafenib</title>"
					}
				},
				{
					"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962124",
					"hasMessage": [
						{
							"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine#bnf_i1643857962124_message_0",
							"hasDitaContent": {
								"@type": "rdf:XMLLiteral",
								"@value": "<p otherprops=\"Severe\" outputclass=\"int-message\">\n  <ph otherprops=\"eslicarbazepine\" outputclass=\"int-heading-drug\">Eslicarbazepine</ph> <ph outputclass=\"int-effect\">decreases</ph> <ph outputclass=\"int-parameter\">the efficacy of</ph> <ph otherprops=\"ulipristal\" outputclass=\"int-drug\">ulipristal</ph>. <ph outputclass=\"int-action\">For FSRH guidance, see <xref format=\"dita\" href=\"treatment-summary/contraceptives-interactions.xml\" type=\"interaction\" rel=\"treatmentsummary\" bnfid=\"PHP92512\">Contraceptives, interactions</xref></ph>.  </p>"
							},
							"hasEvidence": "Anecdotal",
							"hasImportance": "Severe",
							"hasOrder": "1",
							"hasTextContent": "Eslicarbazepine   decreases   the efficacy of   ulipristal .  For FSRH guidance, see  Contraceptives, interactions .    \n\n"
						}
					],
					"hasOrder": "21",
					"hasTitle": {
						"@type": "rdf:XMLLiteral",
						"@value": "<title>Ulipristal</title>"
					}
				}
			],
			"hasSearchLabel": " Eslicarbazepine  | Interactions",
			"hasSearchLink": {
				"@id": "http://bnf.nice.org.uk/interaction/eslicarbazepine.html"
			},
			"hasTitle": {
				"@type": "rdf:XMLLiteral",
				"@value": "<title> Eslicarbazepine </title>"
			},
			"rdfs:label": "eslicarbazepine"
		}
	]
}